pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Previous Studies of EUS-Guided Ablation
| Author (year) | Number | Ablative agent | Median follow-up (mo) | Mean size (mm) | CR (%) | CR ( |
Malignant transformation | Adverse event | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCN | IPMN | Others | Minor | Severe | |||||||
| EUS-guided ethanol ablation | |||||||||||
| Gan et al11 (2005) | 23 | E | 6–12 | 19.4 | 34.8 | 14 | 3 | 6 | 0 | 0 | 0 |
| DiMaio et al12 (2011) | 13 | E | 13.4 | 20.1 | 38.5 | - | 13 | - | 0 | 1 | 0 |
| Caillol et al19 (2012) | 13 | E | 26 | 24 | 84.6 | 13 | - | 0 | 0 | 0 | |
| Park et al16 (2016) | 91 | E | 40 | 30 | 45.1 | 12 | 9 | 70 | 0 | 21 | 0 |
| Gómez et al15 (2016) | 23 | E | 45.8 | 23 | 8.7 | 4 | 15 | 4 | 1 |
1 | 1 |
| EUS-guided ablation Including chemotherapeutic agents | |||||||||||
| Oh et al13 (2011) | 47 | E + P | 21.7 | 31.8 | 61.7 | 9 | - | 38 | 0 | 5 | 0 |
| DeWitt et al14 (2014) |
21 | E + P | 27 | 25 | 47.6 | 6 | 12 | 4 | 0 | 5 | 4 |
| Choi et al17 (2017) | 164 | E + P | 69 | 32 | 72.2 | 71 | 11 | 82 | 0 | 15 | 1 |
| Kim et al23 (2017) | 8 | E | 22.3 | 25.8 | 56 | NA | NA | NA | 0 | 5 | 4 |
| 28 | E + P | ||||||||||
| Moyer et al25 (2017) | 18 | E + G + P | 12 | 25 | 61 | 4 | 19 | 2 | 0 | 4 | 1 |
| 21 | G + P | 12 | 25 | 67 | 0 | 0 | 0 | ||||
EUS, endoscopic ultrasound; CR, complete response; MCN, mucinous cystic neoplasm; IPMN, intraductal papillary mucinous neoplasm; E, ethanol; P, paclitaxel; G, gemcitabine; NA, not available.
*Pancreatic cancer arising from ablation branch-duct type IPMN (the patient refused surgery for remnant branch-duct type IPMN).
†CR in 10 patients, 47.6.